Improvements in patient-reported outcomes in relapsed or refractory large b-cell Lymphoma patients treated with Epcoritamab

Abstract

The impact of cancer therapies on health -related quality of life is an important consideration in treatment decision -making. Patient -reported outcomes were evaluated in a clinical trial of patients with relapsed/refractory large B -cell lymphoma treated with epcoritamab monotherapy (N = 157). Patients reported consistent, marked improvements in lymphoma symptoms, health -related quality of life, and satisfaction with epcoritamab, complementing its favorable clinical efficacy and safety. Background: Patient -reported outcomes were evaluated in EPCORE NHL -1 in patients with relapsed or refractory (R/R) large B -cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037). Materials and Methods: Adults with R/R CD20+ LBCL and >2 prior systemic antilymphoma therapies, including anti-CD20, completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and EQ-5D-3L. A subgroup of patients provided additional feedback in one-on-one qualitative interviews. FACT-Lym and EQ-5D-3L score changes from baseline (CFB) to cycle 9 or end of treatment were interpreted using published minimally important differences (MID). Results: In total, 157 patients (88.5% with diffuse LBCL) were treated (median age, 64 years). In total, 70.7% had >3 prior treatments, 61.1% had primary refractory disease, and 82.8% were refractory to last systemic therapy. FACT-Lym scores exceeded MID thresholds: mean (SD) CFB were 4.4 (15.2), MID 3.0 to 7.0 (FACT -General); 5.9 (7.6), MID 2.9 to 5.4 (FACTLymphoma subscale); 8.4 (15.2), MID 5.5 to 11.0 (FACT -Trial Outcome Index); 10.3 (20.2), MID 6.5 to 11.2 (FACTLym total score). EQ-5D-3L index scores, 0.09 (0.20), MID 0.08, and EQ-VAS scores, 16.6 (22.8), MID 7.0, improved. In 20 qualitative interviews, 88.2% reported symptom improvements; 80.0% were "very satisfied" or "satisfied" with epcoritamab. Conclusions: R/R LBCL patients reported consistent, clinically meaningful improvements in symptoms and HRQoL and satisfaction with epcoritamab.